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Abstract: Metastatic renal cell carcinoma has harboured a poor prognosis for decades with immunotherapy being the only available 
therapy with high toxicity and modest effect. Dependance of renal cell carcinoma oncogenesis on the mTOR pathway has led to clinical 
development of temsirolimus in this setting. This sirolimus derivative has shown clinical efficacy in monotherapy for poor-risk renal cell 
carcinoma leading to an overall survival of 10.8 months in the pivotal phase III trial of this agent. Its specific adverse events consist of 
metabolic dysregulation (hyperlipemia, hyperglycemia), mucositis, rash and pneumonitis which can be severe and need careful moni-
toring and management. In this review, we will discuss of the clinical development of this molecule, its efficacy, its safety profile and 
future perspectives.
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Introduction
Renal  cell  carcinoma  (RCC)  is  the  most  common 
malignancy of the kidney and accounts for 2%–3% 
of  all  adult  cancers.1  Although  surgical  resection 
can  be  curative  in  localized  disease,  prognosis  of 
advanced renal cell carcinoma is very poor with a 
5-year survival rate of 5%–10%. Immunotherapy with 
interferon-α has produced modest survival benefice 
in  clinical  trials2–7  while  high  dose    interleukin-2, 
although active in highly selected patients, is asso-
ciated with severe toxicity.8,9 Phase III studies since 
2007 have emphasized the importance of targeting 
angiogenesis  through  vascular  endothelial  growth 
factor  receptor  (VEGFR)  tyrosine  kinase  inhibi-
tion with sunitinib10 and sorafenib11 or direct VEGF 
inhibition  with  bevacizumab  in  combination  with 
IFN.12,13 These anti angiogenic agents have demon-
strated improved overall survival (sunitinib)14 or pro-
gression free survival (sorafenib15 and bevacizumab/
IFN)16,17 for patients with advanced RCC. The mam-
malian target of rapamycin (mTOR), a member of the 
phosphatidyl inositol 3′ kinase family, is a multifunc-
tional serine-threonine kinase that acts as central reg-
ulator of cell growth, proliferation, and apoptosis.18,19 
It modulates the expression and stability of hypoxia-
  inducible factor (HIF)-1α, which regulates expression 
of VEGF. Temsirolimus, although known as CCI-779, 
is a potent and selective inhibitor of mTOR. It has 
demonstrated its efficacy as first line monotherapy in 
poor-prognosis metastatic RCC in comparison with 
IFN.20 This review will focus on data supporting tem-
sirolimus efficacy in RCC and will address its safety 
profile with emphasis on specific side effects.
Efficacy of Temsirolimus in Renal  
cell cancer
Pharmacokinetics and 
pharmacodynamics
mTOR is a highly conserved serine/threonine kinase 
that forms multimolecular complexes and has a key 
function in apoptosis, cell growth, and tumor pro-
liferation  by  controlling  cellular  catabolism  and 
anabolism.21 mTOR complexes with raptor (regulatory- 
associated protein of mTOR) to form mTORC1 and 
with  rictor  (rapamycin-insensitive  companion  of 
mTOR)  to  form  another  multimolecular  complex 
named  mTORC2.  mTOR  is  activated  through  the 
phosphatidylinositol  3-kinase  (PI3K)  pathway  by 
growth factors receptors such as epidermal growth 
factor  receptor  (EGFR)  or  insulin  growth  factor 
receptor (IGFR), for example (Fig. 1). Once activated, 
mTORC1 phosphorylates its downstream effectors, 
for example, eukaryotic translation initiation factor 
4E-binding protein (4EBP1) and S6 kinase (S6K). 
mTOR  activation  downstream  of  growth  factor 
receptors promotes protein translation, cell growth, 
ribosome biogenesis, metabolism increase, prolifera-
tion and decreased autophagy.
Temsirolimus is a functional analog of rapamycin 
(also  named  sirolimus)  like  everolimus  and 
deforolimus.22 Temsirolimus binds with high affinity 
to  the  immunophilin  FKBP  12  (FK506,  binding 
protein 12) and selectively inhibits mTORC1 but have 
no direct effect on mTORC2.23 Inhibition of mTORC1 
activity is reversible only slowly (5 days).23 Inhibi-
tion of mTORC1 kinase activity results in decreased 
phosphorylation  of  S6K  and  4EBP1.24  Ultimately, 
temsirolimus inhibits the synthesis of various pro-
teins that have important roles in the cell cycle and 
tumorigenesis, such as cyclin D1, p27, and apoptosis 
regulators such as BAD, Bcl2 and p53.25 Inhibition 
of mTORC1 by temsirolimus has also been shown to 
reduce expression of HIF-1α and HIF-2α under both 
normoxic  and  hypoxic  conditions  in  mouse  xeno-
graft models.26 This reduced expression will lead to 
decreased VEGF and PDGF expression. The observed 
clinical efficacy of temsirolimus in patients with renal 
cell carcinoma may be mediated in one hand by inhibi-
tion of efficient HIF-1α translation resulting in inter-
ception of the VEGF/VEGFR and/or PDGF/PDGFR 
signaling cascades and in another way by inhibition 
of protein synthesis that are involved in cell cycle and 
tumorigenesis.
Temsirolimus  is  a  macrocyclic  lactone  and  a 
water-soluble  ester  derivative  of  sirolimus  with 
better chemical stability and solubility which make it 
suitable for intravenous (IV) administration. Follow-
ing IV administration, exposure, measured as total 
area under the concentration time curve (AUC), is 
less than proportional to dose.29 The mean steady-
state volume of distribution of temsirolimus is high, 
indicating  extensive  tissue  distribution;  clearance 
of  the  drug  increases  in  a  less  than  proportional 
manner  with  increased  dosing,  suggesting  satura-
tion  of  drug  metabolism,  modification  of  protein Temsirolimus safety and efficacy in renal cell carcinoma
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binding,  and/or  erythrocyte  sequestration.27  After 
IV injection, temsirolimus is rapidly cleared from 
the plasma and converted in the liver by cytochrome 
CYP 4503A4/5 into sirolimus that becomes the most 
prevalent  drug.  Terminal  half  life  decreases  with 
increasing dose. Excretion is predominantly via the 
feces, with renal elimination of drug and metabolites 
accounting for 4.6% of the administered dose.22 The 
higher relative half-life of the sirolimus metabolite is 
considered to contribute to sustained and clinically 
important exposures for the duration of the weekly 
dosage interval. The mean ratio of sirolimus AUC/
temsirolimus AUC is 2.7.22
Controlled  trials  have  not  been  performed  in 
special populations such as renal impaired, elderly, 
obese  or  hepatic  insufficiency  patients.  Renal 
impairment, in particular, is not expected to influ-
ence  drug  exposure,  and  no  dose  adjustments  of 
temsirolimus are recommended in this population 
because  of  predominant  feces  elimination  of  the 
drug.  In  two  patients  on  hemodialysis  who  were 
treated with temsirolimus 25 mg once weekly for 
metastatic  RCC,  pharmacokinetic  profiles  were 
similar with those observed in patients with normal 
renal function.31
In  phase  I  studies,  temsirolimus  was  initially 
administered at doses that were corrected for body 
surface area (BSA) but it was then showed that the 
degrees of variability between BSA-normalized and 
flat  dosing  were  comparable;  therefore,  flat  doses 
were selected for further evaluation in phase II and 
III trials.30 In the phase II study from Atkins et al, 
3 doses were evaluated: 25,75 and 250 mg: no dif-
ferences  were  seen  in  terms  of  median  survival, 
tumor  response  rates  and  toxicities  between  the 
three doses.32 Thus, temsirolimus, administered as a 
30- to 60-minute IV infusion once weekly at a flat 
dose of 25 mg alone or in combination was the thera-
peutic regimen chosen for subsequent evaluation in 
phase III study.
Temsirolimus in monotherapy
Phase I studies
Temsirolimus efficacy in patient with heavily pretreated 
malignancies was initially observed in two phase 1 
studies. In the study by Raymond et al, 24 patients 
were included with 6 RCC patients30 (Table 1). Temsi-
rolimus was administered once weekly as a 30-minute 
IV infusion after pretreatment with IV antihistamine, 
with escalated doses ranging from 7.5 to 220 mg/m². 
Growth
factors
Growth factor
receptor
mTORC2
RICTOR
RAPTOR
PRA S40
mTOR
mTOR mTORC1
SIN1
RHEB
TSC2
TSC1
S473
T308
AKT
PI3K
PTEN
PDK1
mLST8
mLST8
S6K1
P
P
P
P
4E-BP1
Ribosome biogeneis
Protein synthesis
Metabolism
Cell cycle
IRS1
IRS1
Figure 1. Cell signalling involving mTORC1 and mTORC2 in cancer cells.Hadoux et al
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Table 1. Efficacy of temsirolimus.
Trial ORR pFs (months) 95% cI Os (months) 95% cI
Phase I (monotherapy)25 8.3% ND ND ND ND
Phase I/II (+IFNα)35 11% 9.1 [6.2–13] 18.8 [15–25]
Phase II (monotherapy 25 mg)27 7% 6.3 [3.6–7.8] 13.8 [9–18.7]
Phase III34 Monotherapy 8.6% 5.5 [3.9–7] 10.9 [8.6–12.7]
+IFN α 8.1% 4.7 [3.9–5.8] 8.4 [6.6–10.3]
Abbreviations: ORR, overall response rate = complete response + partial response; PFS, progression free survival; OS, overall survival; 95% CI= 95% 
confidence interval.
Maximum tolerated Dose (MTD) was not reached. 
Confirmed  partial  responses  were  observed  in  two 
patients: in a patient with breast cancer and in a patient 
with  renal  cell  carcinoma  who  received  15  mg/m² 
temsirolimus  after  documented  tumor  progression 
of lung and pleural metastasis under treatment with 
interferon-α and interleukin 2. The partial response 
was observed after 8 weeks of treatment and lasted 
for 6.5 months under therapy. Minor responses lasting 
for 3 and 4.9 months were reported in two additional 
patients with renal cell carcinoma treated at the dose 
of 15 mg/m² and 45 mg/m², respectively. Flat dose was 
adopted because of the lack of variability in compari-
son with BSA-normalized doses. Toxicity analysis of 
this study will be reviewed in another paragraph.
In the study by Hidalgo et al, 63 patients were 
included with 16 having RCC.33 Temsirolimus was 
administered as a 30-minute IV infusion once daily 
on days 1 to 5 of each treatment cycle of 2 weeks with 
doses ranging from 0.75 to 24 mg/m²/d with MTD in 
heavily pretreated patients being 15 mg/m² (grade 3 
aspartate and alanine aminotransaminase elevations, 
vomiting,  diarrhea,  and  asthenia).  One  patient  had 
a  partial  response,  3  had  an  unconfirmed  partial 
response, 3 patients had stable disease. The responses 
in RCC patients in these two phase I studies provided 
the rationale for further evaluation of temsirolimus in 
patient with advanced RCC in phase II studies.
Phase II study
In  phase  II  study  evaluating  temsirolimus  as  a 
monotherapy, 111 patients with advanced refractory 
RCC were randomly assigned to receive 25 mg, 75 mg, 
or 225 mg of temsirolimus every week as a 30-minute 
infusion32 (Table 1). Median age was 57, 69% of the 
patients were male, ECOG performance status (PS) 
was 0 or 1, patients had extensive disease with half of 
them having three or more metastatic sites and were 
heavily pretreated: 28% had had 3 or more previous 
immunotherapy or chemotherapy regimen. The objec-
tive response rate was 7%, which included 1 complete 
response  and  7  partial  responses,  with  26%  minor 
response also reported. The median time to tumor pro-
gression was 5.8 months for the total patient population 
and 6.3 (95% confidence interval (CI) [3.6–7.8], 6.7 
(95% CI [3.5–8.5]) and 5.2 (95% CI [3.7–7.4]) months 
in the 25-, 75- and 250-mg dose group, respectively. 
Median survival was 15.0 months for the total patient 
population and 13.8 (95% CI [9–18.7]), 11 (95% CI 
[8.6–18.6]) and 17.5 (95% CI [12–24.6]) months in the 
25-, 75- and 250-mg dose group, respectively. Addi-
tional analysis on the basis of previously described 
prognostic factors was undertaken. Five poor prognosis 
factors, adapted from Motzer et al,34 were taken into 
account: performance status less than ECOG PS 0 or 1, 
lactate dehydrogenase levels more than 1.5 × upper 
limit of normal, corrected serum calcium levels more 
than 10 mg/dl, serum hemoglobin level less than lower 
limit of normal, and time from initial RCC diagnosis 
to start of first immunotherapy or chemotherapy of less 
than 1 year. Patients were separated into a good-risk 
group that had none of these poor-prognosis factors, 
an intermediate-risk group that had one or two fac-
tors and a poor-risk group that had three or more fac-
tors. The median survivals of the heavily pretreated 
patients in the different risk groups in this study were 
compared with the median survivals of first-line RCC 
patients in the different risk groups treated with IFN-α 
from a previous study.35 For patients in the intermedi-
ate- and poor-prognosis populations, median survivals 
of temsirolimus–treated patients appeared to be 1.6 to 
1.7-fold longer than those of IFN-α–treated patients. 
No  such  advantage  was  seen  in  the  good-progno-
sis patients; however, this may have been due to the 
small number of patients with good prognosis who 
received temsirolimus in this study, resulting in a lack Temsirolimus safety and efficacy in renal cell carcinoma
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of statistical power. Temsirolimus was generally well 
tolerated at all dose levels, hyperglycemia (17%) and 
hypophosphatemia  (13%)  were  the  most  frequently 
grade 3 or 4 adverse events. Results of this phase II 
study led to design a phase III trial comparing temsi-
rolimus alone or in combination with IFN-α to IFN-α 
alone in first line treatment of poor-prognosis RCC.
Phase III trial
Global Advanced Renal Cell Carcinoma (ARCC) Trial, 
a phase III open label multicenter trial, included 626 
patients  with  previously  untreated,  poor-prognosis, 
metastatic RCC who were randomly assigned to receive 
25 mg of weekly IV temsirolimus, 3 million units (U) 
of IFN-α (with an increase to 18 million U) subcutane-
ously three times weekly, or combination therapy with 
15 mg of temsirolimus weekly plus 6 million U of IFN- 
α three times weekly36 (Table 1). At least three of the 
following six poor-prognosis factors were required for 
inclusion: a serum lactate dehydrogenase level of more 
than 1.5 times the upper limit of the normal range, a 
hemoglobin level below the lower limit of the normal 
range; a corrected serum calcium level of more than 
10 mg per deciliter (2.5 mmol per liter), a time from 
initial diagnosis of renal-cell carcinoma to randomiza-
tion of less than 1 year, a Karnofsky performance score 
of 60 or 70, or metastases in multiple organs; these fac-
tors included the 5 adverse prognosis factors described 
by Motzer et al plus the presence of multiple metastatic 
sites. Characteristics of randomized patients were as 
following: median age 59, 69% male, 82% patients 
with Karnofsky performance status of 70 or 60, 82% 
renal clear cell histology, 94% of patients having 3 or 
less poor-prognosis factors. Seventy four percent of 
the patients were classified as poor-risk RCC and 26% 
were classified as intermediate-risk RCC. The primary 
endpoint was overall survival of the temsirolimus group 
and  the  combination-therapy  group  compared  with 
the interferon group. Patients who received temsiroli-
mus alone had superior overall survival (hazard ratio 
(HR) for death: 0.73; 95% CI [0.58–0.92]; P = 0.008) 
and  PFS  (P , 0.001) compared with patients who 
received interferon alone. Overall survival in the com-
bination  therapy  group  did  not  differ  significantly 
from that in the interferon group (HR: 0.96; 95% CI 
[0.76–1.20]; P = 0.70). Median overall survival was 
7.3 months (95% CI [6.1–8.8]), 10.9 months (95% CI 
[8.6–12.7]), and 8.4 months (95% CI [6.6–10.3]); the 
objective response rates were 4.8%, 8.6% and 8.1% in 
the interferon, temsirolimus, and combination therapy 
groups, respectively.
In  exploratory  subgroup  analyses  with  Cox 
proportional-hazards model, the effect of temsirolimus 
on overall survival was found to be greater among 
patients  under  65  years  of  age  than  among  older 
patients (P = 0.02) and among patients with a serum 
lactate dehydrogenase level of more than 1.5 times the 
upper limit of the normal range than among those with 
lower levels (P = 0.008). The most frequently occur-
ring grade 3 or 4 adverse events were asthenia, nausea, 
hyperglycemia,  rash  and  neutropenia.  Mean  dose 
intensity was 30.2 million U/week in the IFN- α alone 
group, 23.1 mg/week in the temsirolimus alone group 
and 10.9 mg/wk of temsirolimus with 13.1 million 
U IFN-α in the combination group. The data from 
this pivotal trial were the basis for May 2007 FDA 
approval of temsirolimus for advanced RCC.
Temsirolimus in combination
Combination with IFN-α
Temsirolimus was first investigated as combination 
therapy with IFN-α in phase I/II study37 (Table 1). 
Patients were enrolled onto a multicenter, ascending-
dose study of temsirolimus (5, 10, 15, 20, or 25 mg) 
administered  intravenously  once  a  week  combined 
with IFN-α (6 or 9 million U) administered subcu-
taneously three times per week. An expanded cohort 
was treated at the recommended dose to obtain addi-
tional safety and efficacy information. Seventy-one 
patients received one of six dose levels. Median age 
was 59 year, 76% of patients were male, 55% had had 
1 or 2 prior chemotherapy regimen, 82% had clear cell 
histology, 55% of the patients had an intermediate-
risk RCC and 24% had a poor-prognosis RCC accord-
ing to MSKCC model. The recommended dose was 
temsirolimus 15 mg/IFN 6 millions U based on dose-
limiting toxicities of stomatitis, fatigue, and nausea/
vomiting,  which  were  observed  at  higher  doses  of 
temsirolimus and IFN-α. The most frequent grade 3 
or 4 toxicities occurring in any cycle included leu-
kopenia,  hypophosphatemia,  asthenia,  anemia,  and 
hypertriglyceridemia. Among patients who received 
the recommended dose (n = 39), 8% achieved partial 
response and 36% had stable disease for at least 24 
weeks. For the entire population, median progression-
free survival was 9.1 months (95% CI [6.2–13]) and Hadoux et al
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median overall survival was 18.8 months (95% CI 
[15–25]). For patients in the recommended-dose cohort 
median  progression-free  survival  was  7.6  months 
(95% CI [5.5–11.0]) and median overall survival was 
22.1 months (95% CI [11.0–26.0]).
This results contrast with those seen in the combi-
nation arm of the ARCC phase III trial. Although the 
chosen dose for the combination arm in the phase III 
trial was the same as the recommended dose of the 
phase I/II study, no differences in overall survival nor 
in progression free survival were seen in compari-
son to the IFN-α alone group. The overall survival 
of the combination group was 8.4 months (95% CI 
[6.6–10.3]) in the ARCC trial in contrast with overall 
survival  of  the  combination  arm  in  the  phase  I/II 
study of 22.1 months (95% CI [11.0–26.0]). In the 
ARCC trial, 30% of the combination group discon-
tinued treatment for adverse event or symptomatic 
deterioration in comparison with 14% of patient in 
the temsirolimus alone group. Therefore, investiga-
tors  attributed  the  reduced  overall  survival  in  the 
combination group to the high rate of serious adverse 
events. However, grade 3–4 adverse events were not 
more important in the phase III trial: asthenia 13.4% 
versus (vs.) 23% in the phase II study, Anemia 18.2% 
vs. 23%, neutropenia 7.2% vs. 33%. Patients in the 
phase III trial had poorer prognosis with 74% of them 
having a poor-risk RCC in comparison with 23% of 
the patients in the phase II study. This could explain 
differences seen in terms of efficacy and toxicity. To 
conclude, owing to the results of the phase III trial, 
temsirolimus has been approved as a monotherapy.
Combination with antiangiogenic agents
Phase  I  studies  have  been  conducted  with  both 
sunitinib and sorafenib. One phase I study evaluated 
temsirolimus in combination with sunitinib in patients 
with  advanced  RCC  with  at  most  two  previous 
regimen.38 At the starting dose, temsirolimus 15 mg 
was administered by IV infusion once weekly, and 
sunitinib 25 mg was administered orally once daily 
for 4 weeks, followed by a 2-week rest period. In the 
first  cohort,  dose-limiting  toxicities  (grade  3  treat-
ment-related toxicities that lasted more or equal to 
7 days) were observed in 2 of 3 patients. One patient 
experienced grade 3 rash during week 3, which led to 
treatment discontinuation. A second patient had grade 
3 thrombocytopenia, cellulitis, and gout during week 3 
and was hospitalized. A third patient experienced rash, 
asthenia, diarrhea, stomatitis, constipation, fever, and 
rectal hemorrhage, all of which were mild in severity. 
The study was terminated because of dose-limiting 
toxicity observed at low starting doses of both agents. 
Another phase I study evaluated temsirolimus in com-
bination with sorafenib: eligible patients were treated 
with  escalating  continuous  oral  doses  of  sorafenib 
(200  and  400  mg  twice  daily)  and  weekly  Temsi-
rolimus IV (15 mg, 25 mg).39 Twenty four evaluable 
patients received 85 courses [median 3; range 1–12] of 
combination therapy. Dose limiting toxicities (DLT) 
were grade 3 typhlitis (n = 1), mucositis (n = 1), hand 
foot syndrome (n = 2), thrombycytopenia/rash (n = 1) 
and creatinine elevation (n = 1). The combination of 
sorafenib and temsirolimus demonstrated significant 
mucocutaneous  toxicity  at  full  doses  of  sorafenib, 
although preliminary PK analyses show no evidence 
of drug-drug interactions. To conclude, phase I studies 
of antiangiogenic tyrosine kinase inhibitors have not 
shown sufficient safety so far.
Bevacizumab has shown its efficacy with improved 
progression free survival and overall survival ranging 
from 18.3 to 23.3 months in the AVOREN trial16 and 
CALGB90206,17 in combination with IFN-α. TORAVA 
is an open label, multicenter, non   comparative phase II 
trial  that  evaluated  temsirolimus  plus  bevacizumab 
combination versus bevacizumab plus IFN-α versus 
sunitinib.40  Preliminary  results  have  been  recently 
presented at the 2010 American Society of Clinical 
Oncology (ASCO) annual meeting. One hundred and 
seventy one untreated metastatic RCC patients with 
ECOG PS #2 and measurable disease were random-
ized to Temsirolimus-Bevacizumab combination (Tem/
Bev) n = 88, sunitinib (S) n = 42 or bevacizumab and 
IFN-α (Bev/IFN) n = 41. Patients were treated until 
disease progression or toxicity. The primary objective 
was to estimate the non-progression rate at 48 weeks 
(NPR-48) for combination arm. Major secondary end-
points were toxicity, response rate and survival. Treat-
ments  were  prematurely  stopped  for  other  reasons 
than progression in 43% (Tem/Bev), 12% (S) and 23% 
(Bev/IFN) patients. Grade 3/4 events were observed 
in 36%, 14% and 27% pts in Tem/Bev, S and Bev/IFN 
arms respectively; two toxic deaths occurred in Tem/
Bev arm. In an intent-to-treat analysis with a median 
follow-up of 43 weeks, NPRs-48 were 43.2% (95% 
CI, 32.7–54.2), 47.6% (95% CI, 32.0–63.6) and 65.9% Temsirolimus safety and efficacy in renal cell carcinoma
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(95% CI, 49.4–79.9) in Tem/Bev, S and Bev/IFN arms 
respectively. Best response rates (RECIST) were 25%, 
24% and 34% respectively. The toxicity profile of the 
Temsirolimus/Bevacizumab combination was higher 
than expected, leading to a high drop-out rate. The 
results do not suggest any evidence of a synergistic/
additive efficacy of this combination. Phase III study 
of combined temsirolimus and bevacizumab (INTO-
RACT) is ongoing.
To conclude, temsirolimus combination with anti-
angiogenic therapies (monoclonal antibody or tyrosine 
kinase inhibitors) has been disappointing so far, with 
high toxicity, phase III studies are still ongoing and will 
probably help to define the best sequence in therapy.
Biomarkers
In an effort to identify potential predictors of response to 
temsirolimus, tumor samples from a subset of patients 
within  a  randomized  phase  II  trial  of  temsirolimus 
in  advanced  renal  cell  carcinoma  were  studied.41 
  Paraffin-embedded tissue sections from patients who 
had received temsirolimus were immunostained with 
antibodies  to  phosphorylatd  S6  ribosomal  protein 
(  phospho-S6),  phosphorylated  Akt  (pAkt),  carbonic 
anhydrase IX and PTEN. In addition, von Hippel-  Lindau 
(VHL) mutational analysis was performed. Immunohis-
tochemistry expression levels and mutational analysis 
were correlated with objective response to   temsirolimus. 
Tissue specimens were obtained from 20 patients who 
were  evaluable  for  both  tumor  response  and  stain-
ing for phospho-S6. In addition, 19 specimens were 
evaluable for pAkt. VHL mutational analysis was per-
formed on 16 samples. Five patients achieved an objec-
tive response (1 partial response/4 minimal responses) 
to temsirolimus. There was a positive association of 
phospho-S6 expression (P = 0.02) and a trend toward 
positive expression of pAkt (P = 0.07) with response 
to temsirolimus. No patient without high expression of 
either phospho-S6 or pAkt experienced an objective 
tumor response. There was no correlation of carbonic 
anhydrase IX and PTEN expression or VHL status with 
response  to  temsirolimus. These  results  suggest  that 
phospho-S6 and pAkt expression could be predictive 
biomarkers  for  response  to  temsirolimus.  However, 
they were obtained on limited samples and need further 
evaluation in larger populations of patients.
A  pharmacodynamic  evaluation  was  performed 
using p70S6 kinase activity measurement in peripheral 
blood mononuclear cells from nine patients with renal 
cell cancer treated with a single dose of 25, 75, or 
250 mg of temsirolimus IV (three patients each) in the 
phase II study by Atkins et al.42 PBMCs were collected 
on days 2,4, and 8 after temsirolimus treatment. Eight 
of the nine patients had evidence of p70S6 kinase 
activity inhibition after treatment that was indepen-
dent of the administered dose. There was a significant 
linear association between time to disease progres-
sion and inhibition of p70s6 kinase activity 24 h after 
treatment (P = 0.004). These results indicated that the 
pharmacodynamic effects of temsirolimus could be 
determined using a p70s6 kinase assay in PBMCs. 
However, the limited sample size in this study does 
not permit to conclude for the value of this assay to 
predict the outcome of patients treated with the drug, 
validation would necessitate larger studies.
Exploratory  subgroup  analyses  from  the ARCC 
trial were conducted to determine if baseline levels 
of the tumor molecular markers PTEN and HIF-1α 
correlated with efficacy in patients treated with tem-
sirolimus  versus  IFN.43  Of  the  416  patients  in  the 
intent-to-treat  population  for  the  temsirolimus  and 
IFN  single  study  arms,  tumor  PTEN  levels  were 
available for 51% of patients and HIF-1α levels were 
available for 60% of patients. Of patients with PTEN 
data, 71% had tumors that stained positively (scoring 
intensity .0). Of patients with HIF-1α data, 62% had 
tumors that stained negatively (scoring intensity = 0) 
for  HIF-1α.  The  baseline  status  of  the  molecular 
markers  PTEN  and  HIF-1α  did  not  correlate  with 
efficacy in renal cell carcinoma patients treated with 
temsirolimus versus IFN. Patients demonstrated OS 
and  progression-free  survival  benefit  when  treated 
with temsirolimus regardless of PTEN and HIF-1α a 
status. Thus, baseline PTEN and HIF-1α levels may 
not predict response to temsirolimus.
Safety Profile of Temsirolimus
Temsirolimus  shares  common  specific  side  effects 
with other sirolimus derivatives such as everolimus 
owing to a classs effect. These specific side effects 
are summarized in Table 2.
Pharmacokinetics considerations
Overall exposure is represented as the composite AUC 
of temsirolimus and sirolimus moieties (AUCsum). 
The severity and duration of some adverse events appear Hadoux et al
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to be related to pharmacokinetic exposure, particularly 
AUCsum.22 Assessment of safety from a phase II study 
in RCC indicated that AUCsum was correlated with 
the severity of thrombocytopenia (P = 0.007), pruritus 
(P = 0.011), and hyperlipidemia (P = 0.04), and with 
duration  of  thrombocytopenia  (P = 0.015) and dry 
mouth (P = 0.036).28 The peak concentration (Cmax) 
of temsirolimus following single doses is also asso-
ciated with toxicity, occurrence and severity of acne 
and mucositis. Acne frequency was 22%, and the odds 
increased  approximately  4%  with  each  10  ng/mL 
increase in Cmax. For mucositis, the probability of 
occurrence  was  approximately  84%,  and  the  odds 
increased by approximately 13% with each 10 ng/mL 
increase in temsirolimus Cmax.22
Metabolic side effects
In the phase I study, 21% grade 3–4 hypercholes-
terolemia and 13% grade 3–4 hypertriglyceridemia 
were reported. All grade hypertriglyceridemia ranged 
from 28% to 33% in phase II studies with grade 3–4 
ranging  from  6  to  13%.  Hyperglycemia  occurred 
in 20% of patients with 17% grade 3–4, hypophos-
phatemia was also reported in 17 to 28% of the patient 
(grade 3–4).30 These adverse events were also reported 
in the ARCC phase III trial with 25% hypertriglyc-
eridemia,  21%  hypercholesterolemia,  18%  hyperg-
lycemia, 6% hypophosphatemia and 11% creatinine 
increase (all grade)44 (Table 2). Among patients with 
such  toxicity,  preexisting  laboratory  abnormalities 
were present in many patients in this study. At base-
line, 42% had grades 1–2 elevated serum glucose and 
one patient (0.5%) had grades 3–4. Additionally, 35% 
of patients had grade 1–2 high total cholesterol/lipid 
levels at baseline. According to temsirolimus safety 
analysis in the phase III study by Bellmunt et al,44 
guidelines have been published regarding manage-
ment  of  these  toxicities.  When  considering  renal 
adverse events, patients in the ARCC study were pre-
disposed to nephrotoxicity because 67% had under-
gone prior nephrectomy. Drug-related renal events in 
the temsirolimus arm (25%) were approximately two 
times greater than the IFN arm (12%). Drug-related 
creatinine increase in the temsirolimus arm (11%) was 
approximately three times greater than the IFN arm 
(4%).  Mechanism  of  renal  insufficiency  following 
temsirolimus administration has not been precisely 
described.  A  case  report  of  Temsirolimus-induced 
Glomerulopathy with proteinuria related to ischemic 
glomerulopathy  and/or  focal  segmental  glomerulo-
sclerosis has been published by Izzedine et al.45
Pneumonitis
The  association  between  sirolimus  and  pulmonary 
toxicity  was  first  described  in  kidney  transplant 
recipients.46 Since then, 41 additional cases have been 
reported in the literature. Lung toxicity with temsirolimus 
has also been described. In the phase II study by Atkins 
and colleagues, out of 111 patients, six patients were 
reported to have had possible nonspecific pneumonitis, 
including five at the 75-mg dose level and one at the 
25-mg dose level. Of these, two were withdrawn from 
additional treatment and four were re-treated, with two 
patients experiencing recurrent pneumonitis.
In  the  phase  III  trial,44  regardless  of  causality, 
26% of patients on temsirolimus had increased cough 
versus 15% on IFN (P = 0.006). Beginning on study 
weeks 9–41, four patients in the temsirolimus group 
had drug-related pneumonitis of differing severity and 
consequences: grade 1 (asymptomatic radiographic 
finding) with no dose interruption (n = 1); grade 2 
with  dose  delay  and  reduction  from  25  to  20  mg 
(n = 1); grade 2 progressing to grade 3 with discon-
tinuation of treatment (n = 1); and grade 3 progress-
ing to grade 4 to 5 with dose delay, then reduction 
from 15 to 10 mg, and finally treatment discontinua-
tion (n = 1) (Table 2). One patient whose pneumonitis 
progressed was treated with antibiotics. In the temsi-
rolimus group, cough was associated with pneumoni-
tis grade 2 or higher; dyspnea was associated with 
pneumonitis  that  progressed  in  severity.  One  fatal 
pneumonitis occured in a patient with a pleural-based 
mass  after  40  weeks  on  temsirolimus.  Death  was 
reported to be due to disease progression although the 
causality of the pneumonitis could not be excluded. 
Patients experiencing pneumonitis in this study were 
managed with antibiotics and/or steroids and/or tem-
sirolimus dose reduction.
In  a  report  of  10  patients  who  had  developped 
pulmonary abnormalities during telmsirolimus treat-
ment for neuroendocrine tumor or endometrial cancer 
(45% of all patients in the trial, n = 22), Duran and 
colleagues described clinical and radiological course of 
these temsirolmius induced pneumonitis.47 Two of the 
ten patients had infectious pneumonitis successfully 
treated with antibiotics. Eight patients were classified Hadoux et al
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as experiencing possible drug-induced pneumonitis, 
6 were non-smokers, 1 was an ex-smoker and 1 was 
an active smoker. Fifty percent of the patients were 
asymptomatic, the other experienced dry cough or 
dyspnea on exertion. Pulmonary abnormalities were 
categorized into two different radiological patterns: 
ground glass opacities with or without diffuse inter-
stitial  disease  and  lung  parenchymal  consolida-
tion. Five patients had pulmonary function tests that 
demonstrated decreased diffusing lung capacity for 
carbon monoxide. Asymptomatic patients were main-
tained under temsirolimus until disease progression, 
dose discontinuation led to resolution of radiological 
abnormalities in all the patients.
To  conclude,  patients  under  temsirolimus  should 
be cautiously monitored for pulmonary toxicity with 
radiographic  or  scannographic  evaluation  during 
treatment.
Dermatologic toxicity
In early phase I study, dermatologic side effects were 
reported in 71% of the 24 patients enrolled, consist-
ing of grade 1 to 2 herpes simplex lesions (5 patients), 
acne-like rash (n = 9), maculopapular rash (n = 12), 
dry skin (n = 9), pruritus (n = 7), and nail disorders 
(n  =  11).  Maculopapular  rashes,  generally  consist-
ing of 5 to 10 cm reactions on face and neck, mainly 
occurred during the first few weeks of treatment and 
were spontaneously reversible. Grade 1 to 2 acne-like 
rash on erythematous base occurred on the face and 
the upper part of the trunk and was reversible with 
and without topical steroid cream. Stomatitis occured 
in 71% of patients; it consisted mainly of 1 to 3 round 
grade 1 to 2 aphtous lesions in the mouth and tongue.
All  grade  dermatologic  toxicity  and  mucosistis 
induced  by  temsirolimus  monotherapy  affected  76 
and 70% of patients in the phase II study respectively 
and 47 and 20% of patients respectively in the phase 
III study with grade 3–4 toxicities affecting less than 
5% of the patients in both studies (Table 2).
Drug interactions through CYP3A4
Because  temsirolimus  and  sirolimus  are  substrates 
of the cytochrome P450 3A4 (CYP3A4) coadmin-
istration  of  drugs  that  inhibit,  induce,  or  compete 
for CYP3A4/5 activity may alter their disposition. 
In  a  pharmacokinetic  assesment  including  healthy 
volunteers,  coadministration  of  5  mg  temsirolimus 
and 400 mg oral ketoconazole, a potent cytochrome 
P450 3A4 blocker, increased sirolimus mean Cmax 
by  2.2-  fold  and AUC  by  3.2-fold  compared  with 
temsirolimus  alone.48  Therefore,  if  a  concomitant 
strong CYP3A4 inhibitor is necessary, a temsirolimus 
dose reduction to 12.5 mg weekly should be consid-
ered. If the strong CYP3A4 inhibitor is discontinued, 
a washout period of approximately 1 week should 
be allowed before the temsirolimus dose is adjusted 
back to the dose used before initiation of the strong 
CYP3A4 inhibitor.44
Other toxicities
Nausea and vomiting occurred respectively in about 
40% and 30% of the patients, diarrhea in 20% to 30% 
patients, grade 3–4 adverse events were inferior to 5%.
Hematologic  toxicity  (Table  2)  occured  in  41% 
(grade  3–4,  19%)  of  the  patients  enrolled  in  the 
phase III studies with most frequent hematologic side 
effect being anemia in 33% of the patient (grade 3–4, 
13%).  Thrombocytopenia  occurred  in  13%  of  the 
patients and leukopenia in 5% (all grades). As far as 
temsirolimus is a sirolimus derivative which is used as 
an immunosuppressive drug, infection-related adverse 
events have been reported to affect 27% of patients (all 
grades, 5% grade 3–4). No abnormal clinical pattern 
of infectious disease has been reported with this drug 
suggesting that with its schedule of weekly administra-
tion, temsirolimus does not display immunosuppres-
sive property. Allergic reactions, mostly low severity, 
occurred in 10 (5%) patients receiving temsirolimus, 
despite premedication with an antihistamine.
conclusion
Temsirolimus has been approved for first line treatment 
of poor-prognosis RCC after having demonstrated its 
efficacy on overall and progression free survival in 
the ARCC phase III study. Toxicity was acceptable 
with most frequent side effects being mucositis, rash, 
hyperglycemia, hyperlipemia and anemia. Although 
rare, drug induced pneumonitis have raised concern 
and need to be monitored in patients receiving mTOR 
inhibitors. Next step to develop this drug is to deter-
mine its position in the sequential therapy of RCC 
and to investigate the potential impact of combination 
therapies. Predictive factors for efficacy ant toxicity 
are obviously needed for any further development and 
biological studies should be included in future trials.Temsirolimus safety and efficacy in renal cell carcinoma
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